<DOC>
	<DOC>NCT02949362</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C13-003.</brief_summary>
	<brief_title>Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>1. Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, subject informed assent) to participate in the study before completing any studyrelated procedures. 2. Subject completed the TEDC13003 study (including subjects in the standard of care treatment arm). 3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol. There are no exclusion criteria for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>